

Type 2 Diabetes in adults (medicines update) Committee meeting 9 Day 1

Date: 17/06/2024



Location: Virtual

Minutes: Final

Committee members present:	
Waqar Shah (Chair)	Present for notes 1 – 7
Chirag Bakhai	Present from item 5
Mimi Chen	Present for notes 1 – 7
Dan Cuthbertson (Topic Adviser)	Present for notes 1 – 7
Natasha Jacques	Present for notes 1 – 7
Sallianne Kavanagh	Present for notes 1 – 7
Sharon McCarthy	Present for notes 1 – 7
Soon Song	Present for notes 1 – 7
Annette Swinkels	Present for notes 1 – 7
Dominic Taylor	Present for notes 1 – 7

In attendance:		
Jackie Durkin	Administrator	Present for notes 1 – 3
Sarah Glover	Information Specialist	Present for notes 1 – 7
James Hall	Senior Guidance Content Designer	Present for notes 1 – 7
James Hawkins	Health Economics Adviser	Present until partway through item 6
Lina Manounah	Technical Analyst	Present for notes 1 – 7
Sarah Matthews	Technical Analyst	Present for notes 1 – 7
Caroline Mulvihill	Technical Adviser, Guideline Lead	Present for notes 1 – 7
Sade Naku	Health Economist	Present for notes 1 – 5
Adam O’Keefe	Project Manager	Present for notes 1 – 7
Nancy Pursey	Assistant Technical Analyst	Present for notes 1 – 7

Muksitur Rahman	Health Economist	Present for notes 1 – 7
Emily Terrazas-Cruz	Senior Technical Analyst	Present for notes 1 – 7
Philip Williams	Finance Analyst	Present for notes 1 – 7

NICE observer:	
Sarah Wilkes, Technical Adviser, Commercial Liaison Team	Present for notes 1 – 7

Apologies:	
Neel Basudev	Committee member
Catherine Bewsey	Committee member
Sithembile Thokozile Chinaire	Committee member
Hussain Contractor	Committee member
Anne Dornhorst	Committee member
Hugh Gallagher	Committee member
John Turner	Committee member
Gosia Wamil	Committee member
Astrid Aregui	Senior Medical Editor, NICE
George Wood	Senior Technical Analyst, NICE

1. Welcome, introductions and apologies				
The Chair welcomed the Committee members and attendees to Day one of the ninth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.				
2. Confirmation of matter under discussion, and declarations of interest				
The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes.				
The Chair asked committee members to verbally declare any new interests, these are noted below:				
Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Chirag Bakhai	Committee member, GP	Clinical Advisor to Health Innovation East	Direct, non-financial professional and personal	Declare and participate Not specific to the scope of the guideline update

The Chair reminded the group that committee member Mimi Chen is excluded from drafting recommendations concerning chronic kidney disease, due to a previously declared conflict of interest. The Chair and a senior member of the Developer's team noted that otherwise, the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of previous meeting

The minutes of the previous meeting were accepted as a true and accurate record.

4. Update on incorporation and integration of NICE TAs

The Chair introduced NICE Health Economics Adviser James Hawkins who provided the committee with an update on the ongoing work to incorporate and integrate NICE Technology Appraisals into its clinical guidelines and the implications for this guideline update.

5. Clinical evidence: Comparing results & Revisiting evidence

The Chair introduced NICE Technical Analyst Sarah Dwyer, who sought input from the committee into the Network Meta-Analyses being conducted in support of this guideline update on behalf of colleagues from NICE's Technical Support Unit at University of Bristol, who were not in attendance.

Senior Technical Analyst Emily Terrazas-Cruz then revisited the clinical evidence previously presented with the committee and compared this evidence with published systematic reviews and NMAs to provide a sense check of the clinical findings to ensure they are in line with other analyses and the committee's clinical understanding.

6. Health economics

The Chair introduced Health Economists Sade Naku and Muksitur Rahman who discussed elements of the health economic modelling being developed in support of the guideline update with the committee.

7. AOB

The Chair reminded the group that Day two of the meeting is scheduled to commence at 10:00 the following day, thanked participants and closed the meeting.

Type 2 Diabetes in adults (medicines update) Committee meeting 9 Day 2

Date: 18/06/2024

Location: Virtual

Minutes: Final

Committee members present:	
Waqar Shah (Chair)	Present for notes 1 – 5
Chirag Bakhai	Present for notes 1 – 5
Catherine Bewsey	Present for notes 1 – 5
Mimi Chen	Present for notes 1 – 5
Hussain Contractor	Present for notes 1 – 5
Dan Cuthbertson (Topic Adviser)	Present until partway through item 4
Natasha Jacques	Present for notes 1 – 5
Sallianne Kavanagh	Present for notes 1 – 5
Sharon McCarthy	Present for notes 1 – 5
Soon Song	Present for notes 1 – 5
Annette Swinkels	Present for notes 1 – 5
Dominic Taylor	Present for notes 1 – 5

In attendance:		
Jackie Durkin	Administrator	Present for notes 1 – 2
Sarah Glover	Information Specialist	Present for notes 1 – 5
James Hall	Senior Guidance Content Designer	Present for notes 1 – 5
James Hawkins	Health Economics Adviser	Present for notes 1 – 5
Sarah Matthews	Technical Analyst	Present for notes 1 – 5
Patrick Muller	Health Economics Adviser	Present for notes 1 – 5
Caroline Mulvihill	Technical Adviser, Guideline Lead	Present for notes 1 – 5
Sade Naku	Health Economist	Present for notes 1 – 5

Adam O’Keefe	Project Manager	Present for notes 1 – 5
Muksitur Rahman	Health Economist	Present for notes 1 – 5
Emily Terrazas-Cruz	Senior Technical Analyst	Present for notes 1 – 5
Philip Williams	Finance Analyst	Present for notes 1 – 5
Jonathan Wray	Senior Analyst – Data and Analytics	Present for notes 1 – 5

NICE observer:	
Sarah Wilkes, Technical Adviser, Commercial Liaison Team	Present for notes

Apologies:	
Neel Basudev	Committee member
Sithembile Thokozile Chinaire	Committee member
Anne Dornhorst	Committee member
Hugh Gallagher	Committee member
John Turner	Committee member
Gosia Wamil	Committee member
Astrid Aregui	Senior Medical Editor
George Wood	Senior Technical Analyst

1. Welcome, introductions and apologies
The Chair welcomed the Committee members and attendees to Day two of the ninth meeting on Type 2 Diabetes in adults (medicines update). The Chair informed the Committee that apologies had been received. These are noted above.
2. Confirmation of matter under discussion, and declarations of interest
The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was initial and subsequent treatment of type 2 diabetes. The Chair asked committee members to verbally declare any new interests, no new interests were declared. The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.
3. Health inequality analysis using real world evidence
The Chair introduced Jonathan Wray and Patrick Muller from NICE who discussed

with the committee and sought its clinical input into work being conducted within NICE using real world evidence in Type 2 Diabetes.

4. Health economics

The Chair re-introduced Health Economists Sade Naku and Muksitur Rahman who further discussed the health economic modelling being developed in support of the guideline update with the committee.

5. AOB

The Chair thanked participants and closed the meeting.

Date of next meeting: Guideline Committee Meeting 9: Monday 17th and Tuesday 18th June 2024

Location of next meeting: Virtual